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Summary
Resistin is an adipocytokine that is associated with inflammation, coronary artery
disease, and other types of cardiovascular disease among patients with normal
kidney function. However, little is known about the association of resistin with
outcomes in kidney transplant recipients. We collected socio-demographic and
clinical parameters, medical and transplant history, and laboratory data from 988
prevalent kidney transplant recipients enrolled in the Malnutrition-Inflammation
in Transplant—Hungary Study (MINIT-HU study). Serum resistin levels were
measured at baseline. Associations between serum resistin level and death with a
functioning graft over a 6-year follow-up period were examined in unadjusted
and adjusted models. The meanSD age of the study population was
51  13 years, among whom 57% were men and 21% were diabetics. Median
serum resistin concentrations were significantly higher in patients who died with
a functioning graft as compared to those who did not die during the follow-up
period (median [IQR]: 22[15–26] vs. 19[14–22] ng/ml, respectively; P < 0.001).
Higher serum resistin level was associated with higher mortality risk in both
unadjusted and fully adjusted models: HRs (95% CI): 1.33(1.16–1.54) and 1.21
(1.01–1.46), respectively. In prevalent kidney transplant recipients, serum resistin
was an independent predictor of death with a functioning graft.
Introduction
Resistin is an adipose tissue-specific hormone, which was
discovered in the past decade by three independent research
groups [1]. It is a 12.5-kDa cysteine-rich protein that has
different isoforms circulating in the bloodstream [2–4].
Resistin is linked to insulin resistance, hence the name.
Resistin also appears to play an important role in the
immune system. It is largely synthesized in macrophage
cells; induces the production of inflammatory cytokines;
elevates the expression of cell adhesion molecules, such as
vascular cell adhesion molecule (VCAM), intracellular cell
adhesion molecule (ICAM), and monocyte chemotactic
protein (MCP); and promotes vascular smooth muscle pro-
liferation and monocyte vascular infiltration [5–7].
Resistin may influence patient outcomes via multiple
diverse biological pathways. Although controversial,
human data suggest that resistin is linked to insulin resis-
tance and obesity [8–10]. Other studies have found that
resistin functions as a pro-inflammatory cytokine and its
serum level was shown to correlate with serum tumor
necrosis factor-alpha (TNF-alpha) and interleukin 6 (IL-6)
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levels [11]. Higher resistin levels have also been associated
with chronic inflammatory diseases such as rheumatoid
arthritis or inflammatory bowel disease, and may play a
role in the pathophysiology of atherosclerosis and endothe-
lial cell injury [12,13]. Based on these data, resistin may be
a biomarker and potentially a pathophysiological factor in
the development of cardiovascular disease and death [14–
17].
While there have been a number of prior studies examin-
ing resistin in patients with chronic kidney disease (CKD),
only one study to date has been performed among kidney
transplant recipients [18]. In this study, higher serum resis-
tin was associated with markers of chronic inflammation
(e.g., high-sensitive C-reactive protein [CRP] and white
blood cell count) as well as impaired kidney function.
Based on these results, resistin may be a risk factor for mor-
tality in patients with CKD. To further inform the field,
our primary aim was to analyze the association between
serum resistin levels and outcomes in prevalent kidney
transplant recipients. We hypothesized that higher resistin
levels were associated with higher risk of death and graft
loss.
Methods
Study population and data collection
We recruited all prevalent kidney transplant recipients
(n = 1214), who were followed at a single transplant outpa-
tient clinic at the Department of Transplantation and Sur-
gery at Semmelweis University Faculty of Medicine in
Budapest, Hungary, during the inclusion period of Decem-
ber 31, 2006 to December 31, 2007 (Malnutrition-Inflam-
mation in Transplant—Hungary Study [MINIT-HU
Study]) [19–25]. Baseline characteristics were defined as
data detected at the time of cohort inclusion. We excluded
patients who at the time of study entry experienced acute
rejection within the last 4 weeks, were hospitalized at the
study entry, received kidney transplantation in the previous
3 months, or had acute infection or bleeding. The study
cohort algorithm is shown in Figure S1 and resulted in 988
patients.
Medical history and socio-demographic data were col-
lected at baseline, including information on age, sex, etiol-
ogy of chronic kidney disease, co-morbidities (the modified
Charlson Comorbidity Index (CCI)), and transplantation-
related data including immunosuppressant medications
[26]. Estimated glomerular filtration rate (eGFR) was cal-
culated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [27].
The study was approved by the Ethics Committee of
Semmelweis University (49/2006). Before enrollment,
patients received detailed written and verbal information
regarding the aims and protocol of the study and gave writ-
ten consent to participate.
Laboratory data
All laboratory data were collected and measured at the
baseline clinic visit and included resistin, TNF-alpha, IL-6,
blood hemoglobin (Hb), serum CRP, serum creatinine,
blood urea nitrogen (BUN), and serum albumin levels.
Serum resistin concentration was measured using
immunoassay kits based on solid-phase sandwich enzyme-
linked immunosorbent assay (ELISA) (R&D Systems, Min-
neapolis, MN, Coefficient of Variation <10%).
Kidney transplantation-related data and donor
characteristics
Transplant-related data were obtained from the medical
records and included medications (including current
immunosuppressive treatment), transplant vintage (i.e.,
time elapsed since the date of transplantation), length of
time on dialysis prior to transplantation, type of allograft,
history of acute rejection(s) that were treated after trans-
plantation, human leukocyte antigen (HLA) mismatch,
panel-reactive antibodies titer (PRA), cold ischemia time
(CIT), donor age and sex, and history of delayed graft func-
tion. Total time with end-stage renal disease (ESRD) was
defined as the total time on any type of renal replacement
therapy including any type of dialysis or kidney transplan-
tation.
Immunosuppressive therapy
Standard immunosuppressive therapy included pred-
nisolone, with either cyclosporine (CsA) A microemulsion
formulation (Neoral) or tacrolimus, combined with
mycophenolate mofetil (MMF) or azathioprine or siroli-
mus.
Outcome ascertainment
Patients were followed for a median (IQR) period of 76
(46–79) months. The primary outcome of interest was all-
cause death with a functioning graft. We also assessed the
association between baseline serum resistin level and
death-censored graft loss as a secondary outcome. Deaths
and re-initiations of maintenance dialysis were ascertained
from hospital medical records. Deaths were validated by
cross-referencing with the Hungarian Central Office of
Administrative and Electronic Public Service record, which
is the government agency maintaining official vital status
data.
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Statistical analysis
Statistical analyses were carried out using STATA 13 (Stata-
Corp, College Station, TX, USA) software. Descriptive data
were summarized using proportions, means (standard
deviation, SD), or medians [IQR] as appropriate. Categori-
cal variables were compared using chi-square tests, and
continuous variables were compared using Student’s t-test
or the Mann–Whitney U-test as appropriate and P for
trend test. Correlations between covariates were assessed by
Pearson correlation coefficients. In all analyses, two-sided
tests were used and the results were considered statistically
significant if the P-value was <0.05.
The association between baseline serum resistin level and
deaths with a functioning graft was assessed using Cox-pro-
portional regression analysis and Kaplan–Meier plots with
the log rank test. Analogous analyses were also conducted
for death-censored graft loss as a secondary outcome. Pro-
portional hazards assumptions were tested using scaled
Schoenfeld residuals. The variables entered in the multi-
variable-adjusted models were selected based on theoretical
considerations; we included predictors in the models which
were known to be associated both with resistin levels and
with mortality based on scientific evidence, and which were
available in our database. Five Cox regression models were
examined with incremental levels of multivariable adjust-
ment: (i) unadjusted model; (ii) model 1 was adjusted for
age and sex; (iii) model 2 was adjusted for variables in
model 1, as well as baseline eGFR, CCI, ESRD time, and
diuretic treatment at baseline; (iv) model 3 was adjusted
for variables in model 2, as well as serum albumin level and
body mass index (BMI); (v) model 4 was adjusted for vari-
ables in model 3 and cold ischemia time, PRA level, HLA
mismatch, number of transplantations, TNF-alpha, IL-6,
and CRP levels.
In sensitivity analyses, we also assessed the association
between baseline resistin levels and all-cause mortality.
Because death with functioning graft and graft loss are
competing events, a competing risk model was used to bet-
ter analyze the risk of death with a functioning graft using
the Fine and Gray model [28]. Our event of interest was
death with functioning graft, and the competing event was
graft failure. We also performed subgroup analyses in clini-
cally relevant subgroups of patients, and the P-values of the
interaction terms were calculated.
Only 6% of the data were missing in our final model;
therefore, we had all the variables from 933 patients
(Table S6). Missing values were not imputed in primary
analyses, but were substituted in our sensitivity analyses
with the use of multiple imputation procedures (creating 5
datasets) using STATA’s “mi” set of command in sensitivity
analyses (Table S3). We followed the STROBE guidelines in
our article (Table S7).
Results
Demographics and baseline characteristics
Baseline characteristics are shown in Table 1. The mean
ageSD of the population was 51  13 years, 57% were
male, 21% had diabetes mellitus, 9% had coronary heart
disease, and the median time since kidney transplantation
was 72 months.
Patients in the highest resistin tertile had significantly
lower residual graft function, higher levels of inflammatory
markers, lower BMI and triglyceride levels and spent more
time on any type of renal replacement therapy (i.e., longer
ESRD time) than patients in the lower resistin tertiles
(Table 1).
Serum resistin levels showed strong negative correlation
with eGFR (Fig. 1); weaker negative correlations with BMI,
abdominal circumference, and triglyceride levels; and had
positive correlations with adiponectin, inflammatory, and
demographic parameters as shown in Table S1.
Mortality
Figure 2 shows the association between higher serum resis-
tin level in 10 ng/ml increments and outcomes. Serum resis-
tin levels at baseline were significantly higher in patients who
died with a functioning graft as compared to patients who
were alive with functioning graft at the end of the study per-
iod (median[IQR]: 22[15–26] and 19[14–22] ng/ml, respec-
tively). Patients in the lower serum resistin tertile had early
separation in their survival curves from their counterparts in
the higher serum resistin tertiles (Fig. 3 panel a). There were
182 deaths over a median follow-up period of 76 months;
the rate of death with a functioning graft was 36/1000
patient-years (95%CI: 31–42). Crude mortality rates by
resistin tertiles and outcomes are presented in Table S2.
Figure 4 panel A shows a strong linear positive associa-
tion of serum resistin as a continuous variable and risk of
death using fractional polynomials and cubic splines. This
analysis has revealed that each 10 ng/ml higher serum resis-
tin level was associated with 33% higher risk of mortality
(HR [95%CI]: 1.33 [1.16–1.54]), and this strong associa-
tion remained qualitatively the same even after adjustment
for confounders in our fully adjusted model: HR (95%CI):
1.21 (1.01–1.46) (Fig. 2, Table S3).
Compared to patients in the lowest serum resistin ter-
tile, those in the middle tertile had similar mortality risk
(HR [95%CI]: 1.01 [0.68–1.49]), while patients who were
in the highest tertile showed a trend toward higher mor-
tality risk in the multivariable-adjusted model: HR (95%
CI): 1.22 (0.82–1.84) (Table S4). We also assessed the
association between serum resistin level in 10 ng/ml
increments and mortality risk in various subgroups of
patients using multivariable-adjusted Cox regression anal-
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Table 1. Baseline characteristics of the 988 kidney transplant recipients.
All patients
(n = 988)
First tertile
of serum resistin
(n = 330)
Second tertile
of serum resistin
(n = 329)
Third tertile of
serum resistin
(n = 329) *P value
Resistin (ng/ml) 20.60  9.03 12.68  2.47 18.66  1.80 30.48  8.43 <0.001
Demographic parameters
Graft loss (%) 20 12 17 32 <0.001
Mortality (%) 18 15 18 23 <0.001
Age (year) 51  13 52  12 51  13 50  13 0.038
Sex—Male (%) 57 61 56 55 0.324
Time since Tx (month) 72 (114-39) 64 (110-36) 68 (111-37) 83 (119-47) <0.001
Previous time on
dialysis (month)
20 (38-9) 18 (36-8) 22 (38-10) 22 (42-8) 0.041
Total ESRD time (month) 108 (154-68) 96 (147-63) 103 (152-64) 118 (162-84) <0.001
Number of Tx.(%)
1 88 90 88 86 0.111
2 10 9 10 13
3 1 1 2 1
Charlson comorbidity index 2 (4-2) 2 (4-2) 2 (4-2) 2 (3-1) 0.937
Presence of HT (%) 94 94 93 94 0.698
Presence of DM (%) 21 22 22 19 0.552
Presence of coronary
heart disease (%)
9 9 8 10 0.609
Smoking (%) 19 21 16 20 0.242
Kidney function-related parameters
Hgb (g/l) 134.7  17.0 138.6  14.8 135.2  16.6 130.4  18.4 <0.001
eGFR (CKD-EPI) (ml/min/1.73 m²) 50.9  21.0 61.3  18.2 51.4  19.2 39.8  19.7 <0.001
Serum albumin (g/l) 40.2  4.1 40.8  3.5 40.4  4.2 39.5  4.6 <0.001
Creatinine (umol/l) 144.8  82.5 113.3  38.4 134.5  50.6 186.7  116.6 <0.001
HCT (%) 38.4  4.7 39.2  4.1 38.6  4.6 37.5  5.1 <0.001
ESA treatment (%) 10 6 8 17 <0.001
Inflammation
WBC (109/l) 7.9  2.3 7.2  2.0 7.9  2.2 8.6  2.5 <0.001
CRP (mg/l) 3.1 (6.8-1.5) 2.6 (5.3-1.4) 3.1 (7.1-1.4) 3.9 (8.3-1.6) <0.001
IL6 (pg/ml) 3.1 (3.6-1.5) 1.9 (3.9 3.0 (3.6-1.3) 3.6 (4.3-1.4) 0.001
TNF-alpha (pg/ml) 2.1 (2.8-1.5) 1.8 (2.3-1.3) 2.2 (2.9-1.6) 2.3 (3.2-1.7) <0.001
Nutrition
BMI (kg/m2) 27.0  4.9 27.5  4.9 27.0  4.9 26.5  4.9 0.002
Abdominal circumference (cm) 99  14 100  13 98  15 98  15 0.036
HDL (mmol/l) 1.3  0.4 1.4  0.5 1.3  0.4 1.2  0.4 <0.001
LDL (mmol/l) 3.2  1.0 3.3  0.9 3.2  0.9 3.0  1.0 <0.001
Cholesterine (mmol/l) 5.5  1.3 5.7  1.2 5.5  1.2 5.3  1.8 <0.001
Triglyceride (mmol/l) 1.7 (2.5-1.2) 1.7 (2.5-1.2) 1.7 (2.5-1.2) 1.7 (2.5-1.2) 0.904
Transplantation-related data
Primary cause of ESRD (%)
Chronic GN 23 22 22 24 0.235
Chronic TIN 13 12 12 16
PKD 18 21 18 16
Diabetic nephropathy 5 5 6 3
Hypertensive nephropathy 7 5 8 7
Others or unknown 23 20 24 24
Cold ischemic time (min) 1249  347 1218  354 1249  355 1281  330 0.008
History of delayed graft
function (%)
26 22 29 27 0.151
PRA mean (min, max) 3.80 (0–85) 2.10 (0–60) 4.20 (0–85) 5.10 (0–70) 0.015
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yses (Figure S2 panel A). Similar associations between
increased serum resistin levels and higher mortality risk
were detected in almost all subgroups, although tests of
interactions were statistically significant in some sub-
groups indicating effect modification by age, BMI, and
serum albumin levels.
In sensitivity analysis, we assessed the association
between serum resistin levels and all-cause mortality. Qual-
itatively similar associations were found using all-cause
mortality as an alternative outcome (Figs 2, 3 panel b, S2
panel b, and Tables S2–S4). Similar results were found after
multiple imputations (Table S3). Similar trends were found
in our competing risk regression models (Table S5).
Graft loss
Patients in the lowest serum resistin tertile had early sepa-
ration in the graft survival curve from their counterparts in
higher serum resistin tertiles (Fig. 3 panel c). There were
201 graft losses, and the event rate was 40/1000 patient-
years (95%CI: 35–46), which positively correlated with
higher serum resistin level (Table S2).
Figure 4 panel C shows a strong linear and positive asso-
ciation between serum resistin level and risk of graft loss
using fractional polynomials and cubic splines. Each 10 ng/
ml higher serum resistin level was associated with a 71%
higher risk of graft loss (HR [95%CI]: 1.71 [1.54–1.89]),
and this association remained qualitatively the same even
after adjustment for confounders in our fully adjusted
model: HR (95%CI): 1.71 (1.49–1.96) (Fig. 2, Table S3).
Compared to patients in the lowest serum resistin tertile,
patients in the middle tertile experienced a 53% higher risk
of graft loss (HR [95%CI]: 1.53 [0.99–2.36]) while those in
the highest tertile had a threefold higher risk: HR (95%CI)
3.06 (2.03–4.60) in multivariable-adjusted models
Table 1. continued
All patients
(n = 988)
First tertile
of serum resistin
(n = 330)
Second tertile
of serum resistin
(n = 329)
Third tertile of
serum resistin
(n = 329) *P value
HLA mismatch (%)
0 1 1 1 1 0.438
1 5 6 5 4
2 22 20 20 25
3 46 48 44 46
4 21 20 24 20
5 4 4 4 4
6 1 2 2 0
Immunosuppression
Steroid use (%) 81 77 82 85 0.027
Cyclosporine use (%) 49 46 49 51 0.347
Tacrolimus use (%) 43 43 43 43 0.992
Azathioprine use (%) 4 4 6 2 0.077
MMF use (%) 78 76 79 79 0.664
Sirolimus use (%) 8 12 8 4 0.001
Everolimus use (%) 2 3 2 2 0.549
HT, hypertension; DM, diabetes mellitus; ESRD, end-stage renal disease; Hgb, hemoglobin; eGFR, estimated GFR; CKD-EPI, Chronic Kidney Disease –
Epidemiology Collaboration; ESA, erythropoietin-stimulating agent; HCT, hematocrit; WBC, white blood cell count; CRP, C-reactive protein; IL6, inter-
leukin-6; TNF-alpha, tumor necrosis factor-alpha; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; GN, glomeru-
lonephritis; TIN, tubulo-interstitial nephritis; PKD, polycystic kidney disease; PRA, platelet-reactive antigen; HLA, human leukocyte antigen; MMF,
mycophenolate mofetil; number of Tx: number of transplantations. Values are in median with interquartile range or in meanSD. The bold values are
the meanstandard deviation (SD) of the serum resistin level.
*P value comparing the resistin subgroups.
Figure 1 Association between serum resistin level and estimated
glomerular filtration rate (eGFR).
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(Table S4). Similar results were found after multiple impu-
tations (Table S3). Similar associations between higher
serum resistin levels and higher risk of graft loss were
detected in almost all subgroups (Figure S2 panel C).
Discussion
To the best of our knowledge, this is the first observational
cohort study demonstrating that higher serum resistin
levels are independently associated with adverse outcomes
in a large cohort of prevalent kidney transplant recipients.
We hypothesized that higher resistin levels were associated
with higher risk of mortality and graft loss. In our prevalent
cohort, higher serum resistin level was associated with
higher mortality risk in both unadjusted and fully adjusted
models. Each 10 ng/ml elevation of serum resistin was
associated with 33% higher risk of mortality in unadjusted
models, and 21% higher risk of mortality after adjustments.
Serum resistin levels showed strong negative correlations
with residual graft function and weakly positive association
Figure 2 Association between the resistin level in 10 ng/ml increments
and outcomes using Cox-proportional models and logistic regression
models in 988 kidney transplant recipients. Data were adjusted for the
following: model 1: age, sex; model 2: model 1 covariates and baseline
eGFR, CCI, ESRD time, diuretic treatment; model 3: model 2 and albu-
min level, BMI; model 4: model 3 and cold ischemic time, PRA level,
HLA mismatch, number of transplantations, TNF-alpha, IL-6, and CRP.
Abbreviations: eGFR: estimated glomerular filtration rate; ESRD time:
total time spent on any type of renal replacement therapy; CCI: Charl-
son Comorbidity Index, BMI: body mass index; PRA: panel-reactive anti-
bodies titer; HLA: human leukocyte antigen; TNF-alpha: tumor necrosis
factor-alpha; IL-6: interleukin 6; CRP: C-reactive protein.
(a)
(b)
(c)
Figure 3 Kaplan–Meier curves showing the association between
serum resistin tertiles and death with a functioning graft (panel a), all-
cause mortality (panel b), and death-censored graft loss (panel c) for
988 kidney transplant recipients.
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with inflammatory markers, while no association was
detected between serum resistin and body weight or pres-
ence of diabetes. There are two potential explanations for
elevated serum resistin levels in the kidney transplant recip-
ient population, which include (i) impaired renal excretion
of resistin, and (ii) increased synthesis of resistin caused by
cytokines. Similar associations between serum resistin, kid-
ney function, and inflammation have been observed in pre-
vious studies [29]. Axelsson et al. [30] examined the role of
resistin in 239 individuals with CKD and found strong
associations of resistin with GFR and inflammatory mark-
ers. Malyszko et al. [29] demonstrated that patients on
hemodialysis with residual kidney function have signifi-
cantly lower resistin levels than those without residual renal
function, supporting the hypothesis that resistin is excreted
via the kidney. To the best of our knowledge, only one
study has assessed these associations in kidney transplant
recipients [18]. Among 80 transplant recipients, Malyszko
et al. [18] found that resistin was associated with both
eGFR and inflammatory markers such as CRP and IL-6.
According to Marouga et al. [31], resistin could be the
mechanistic link between the protein energy wasting syn-
drome and inflammation, in which patients with lower
BMI have higher levels of inflammatory factors as well as
resistin levels. In our study, we found only weak associa-
tions with these inflammatory markers, while the associa-
tion with residual renal function was more prominent.
There was also a strong association between higher
serum resistin level and higher risk of death in our cohort.
Each 10 ng/ml higher serum resistin was associated with a
17% higher risk of death even after adjusting for con-
founders such as socio-demographic parameters, residual
kidney function, nutritional/inflammatory parameters,
comorbidities, and transplantation-related covariates. Our
findings are similar to what was recently described across
various types of heterogeneous populations in a meta-ana-
lysis, although not all studies detected a resistin–mortality
association [32,33]. There are several different pathways
that may explain the association between resistin and death.
First, increased serum resistin may lead to death via cardio-
vascular processes. In a prospective study with 6 years of
follow-up, Frankel et al. [34] found that higher levels of
resistin were associated with a higher risk of incident heart
failure. Similar results were found in a prospective study by
Weikert et al. [15], who observed that patients in the high-
est resistin quartile had two times higher risk of myocardial
infarction compared to patients in the lowest quartile. Sev-
eral studies have investigated the association of resistin with
mortality in patients with impaired kidney function,
although none have been conducted in kidney transplant
populations. Spoto et al. [35] investigated the association
of resistin with both all-cause and cardiovascular mortality
in 231 patients with ESRD. Strong associations were
observed between serum resistin and mortality, although
serum adiponectin was a strong effect modifier of this rela-
tionship. In contrast, Chung et al. [36] reported that the
lowest serum resistin level was associated with the highest
rate of hospitalization among hemodialysis patients. In
(a)
(b)
(c)
Figure 4 Association of resistin levels with death with functioning
graft (panel a), all-cause mortality (panel b), and death-censored graft
loss (panel c) in unadjusted Cox regression models in 988 kidney trans-
plant recipients.
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animal studies, Zhang et al. [37] found that higher resistin
levels caused myocardial dysfunction and that the differen-
tial molecular and vascular effects of resistin could lead to
coronary heart disease, kidney damage, as well as graft loss.
Further studies are needed to determine the mechanisms
underlying the association between serum resistin, cardio-
vascular disease, and death.
Another novel finding in our study was the association
between increased serum resistin level and higher risk of
graft loss in our population. While a number of studies
have examined the association between resistin and kidney
function, there have been no prior studies investigating
the association of resistin with graft loss [38]. As previ-
ously mentioned, serum resistin levels show strong corre-
lations with inflammatory markers and may possibly play
an important role in endothelial function. Resistin itself is
enhancing the synthesis of inflammatory cytokines in
macrophages and in in vitro experiments. Resistin has
been shown to be associated with higher expression of cell
adhesion molecules (VCAM, ICAM, MCP) [5,7]. In addi-
tion, Calabro et al. [6] has found that increased resistin
levels have a dose-dependent association with smooth
muscle proliferation and monocyte vascular infiltration in
human aortic smooth muscle cells. In addition, Verma
et al. [39] discovered that resistin stimulating the release
of endothelin-1 and nitrogen monoxide in endothelial
cells. The association between resistin and endothelin-1
was also examined in a clinical study. [40] All these vas-
cular and inflammatory effects could lead to endothelial
dysfunction, glomerulo-sclerosis, and tubulo-interstitial
fibrosis resulting in higher risk of graft loss.
The possible clinical relevance of our findings in kidney
transplant recipients is not immediately clear at this point.
Recently, in vitro studies have suggested that statin use
could lower resistin and TNF-alpha levels preventing graft
loss or cardiovascular disease; however, a recent clinical
study did not support this hypothesis [41,42]. On the other
hand, statins such as fluvastatin, which decrease resistin
levels, have shown a positive impact on kidney transplant
population outcomes [7,43,44]. The other promising group
of medications includes thiazolidinediones, which have
been shown to inhibit resistin synthesis in vitro [45]. How-
ever, it has yet to be shown that lowering resistin levels with
medications can directly improve outcomes in the kidney
transplant population.
The strength of our study includes its examination of a
large cohort of kidney transplant recipients, a relatively
long period of follow-up time, and minimal missing data
given the protocolized study design and data collection. In
addition, our analyses accounted for important con-
founders of the resistin–mortality association such as resid-
ual graft function and inflammatory markers. To the best
of our knowledge, our study is the first to investigate the
association of serum resistin with mortality and graft loss
in prevalent kidney transplant recipients.
The results of our study should be tempered by some
potential limitations. One of the major limitations of this
study was that serum resistin level was measured only once
at baseline; therefore, we did not have the ability to follow
change in serum resistin levels over time and perform time-
dependent analysis. Furthermore, we do not have serum
resistin measurement performed prior to kidney transplan-
tation, so we were not able to adjust for these values in our
models. Moreover, a prevalent cohort has been used to
assess the association between serum resistin and outcomes,
which could have introduced selection bias. In addition, we
do not have information about proteinuria, which could be
an important confounder. Additionally, models could only
be adjusted for identified confounders for which we had
available data. Therefore, we cannot rule out residual con-
founding. Due to data limitations, we could not analyze
associations of serum resistin with cause-specific mortality.
Conclusions
In our relatively large and contemporary cohort of almost
one-thousand kidney transplant recipients, we found that
serum resistin showed moderate-to-strong associations
with residual graft function and weak correlations with
inflammatory markers. In addition, we reported strong, lin-
ear associations between serum resistin level and clinical
outcomes such as mortality and graft loss. Further studies
are needed to examine whether treatments decreasing
serum resistin can favorably impact outcomes in kidney
transplant recipients.
Authorship
KN: contributed to analysis of the data, interpretation of
data, and wrote the manuscript. AU: contributed to data
collection and writing the manuscript. MEC: contributed
to data collection and writing the manuscript. AR: con-
tributed to data collection and writing the manuscript.
CPK: contributed to interpretation of data and writing the
manuscript. ZM: contributed to writing the manuscript.
CMR: contributed to writing the manuscript. IM: con-
tributed to data collection, contributed to interpretation of
data, and writing the manuscript. MZM: contributed to
data collection, contributed to analysis of the data, inter-
pretation of data, and writing the manuscript.
Funding
This study was supported by grants from the National
Research Fund (OTKA) (F-68841; KTIA-OTKA-EU 7KP-
HUMAN-MB08-A-81231), ETT (206/09), the Hungarian
© 2015 Steunstichting ESOT 29 (2016) 352–361 359
Nagy et al. Resistin and outcomes
Kidney Foundation, Hungarian Society of Hypertension,
Hungarian Society of Nephrology, and the Foundation
for Prevention in Medicine. M.Z.M. received grants from
the National Developmental Agency (KTIA-OTKA-EU
7KP-HUMAN-MB08-A-81231) from the Research and
Technological Innovation Fund and was also supported by
Hungarian Kidney Foundation.
Acknowledgements
The authors thank the patients and the staff in the Depart-
ment of Transplantation and Surgery, Semmelweis Univer-
sity, Budapest, Hungary.
Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Flow chart of patients’ selection.
Figure S2. Hazard ratios (95% confidence intervals) of
the association between resistin (per 10 ng/ml increase) and
death with a functioning graft (panel a), all-cause mortality
(panel b) and death censored graft loss (panel c) using mul-
tivariable adjusted Cox regression analyses in 988 kidney
transplant recipients in various subgroups of patients (P-
values are the significance levels of the interaction terms).
Table S1. Correlation between serum resistin level and
different variables.
Table S2. Number observed events and mortality rates
for death with functioning graft, all-cause mortality and
graft loss divided by resistin tertiles.
Table S3. Association between resistin (per 10 ng/ml
increments) and outcomes in 988 kidney transplant recipi-
ents.
Table S4. Association between different resistin tertiles
and outcomes in 988 kidney transplant recipients.
Table S5. Association of serum resistin with graft-loss
censored mortality in 988 kidney transplant recipients esti-
mated with Fine-Gray competing-risks analysis, where death
with a functioning graft was the event of interest and graft
failure before death was considered as a competing event.
Table S6. Number of missing values of the variables used
for adjusted Cox regression models.
Table S7. STROBE Guideline.
References
1. Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin
links obesity to diabetes. Nature 2001; 409: 307.
2. Aruna B, Ghosh S, Singh AK, et al. Human recombinant
resistin protein displays a tendency to aggregate by forming
intermolecular disulfide linkages. Biochemistry 2003; 42:
10554.
3. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L.
Disulfide-dependent multimeric assembly of resistin family
hormones. Science 2004; 304: 1154.
4. Kusminski CM, McTernan PG, Kumar S. Role of resistin in
obesity, insulin resistance and Type II diabetes. Clin Sci
(Lond) 2005; 109: 243.
5. Burnett MS, Lee CW, Kinnaird TD, et al. The potential
role of resistin in atherogenesis. Atherosclerosis 2005; 182:
241.
6. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin pro-
motes smooth muscle cell proliferation through activation
of extracellular signal-regulated kinase 1/2 and phos-
phatidylinositol 3-kinase pathways. Circulation 2004; 110:
3335.
7. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA,
Rader DJ. Resistin is an inflammatory marker of atheroscle-
rosis in humans. Circulation 2005; 111: 932.
8. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relation-
ship between plasma resistin concentrations, inflammatory
chemokines, and components of the metabolic syndrome in
adults.Metabolism 2008; 57: 494.
9. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum
resistin (FIZZ3) protein is increased in obese humans. J Clin
Endocrinol Metab 2003; 88: 5452.
10. Asano H, Izawa H, Nagata K, et al. Plasma resistin concen-
tration determined by common variants in the resistin gene
and associated with metabolic traits in an aged Japanese
population. Diabetologia 2010; 53: 234.
11. Fargnoli JL, Sun Q, Olenczuk D, et al. Resistin is associated
with biomarkers of inflammation while total and high-mole-
cular weight adiponectin are associated with biomarkers of
inflammation, insulin resistance, and endothelial function.
Eur J Endocrinol 2010; 162: 281.
12. Fadda SM, Gamal SM, Elsaid NY, Mohy AM. Resistin in
inflammatory and degenerative rheumatologic diseases.
Relationship between resistin and rheumatoid arthritis dis-
ease progression. Z Rheumatol 2013; 72: 594.
13. Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M,
Voudouri T, Kouroumalis EA. Circulating levels of leptin,
adiponectin, resistin, and ghrelin in inflammatory bowel
disease. Inflamm Bowel Dis 2006; 12: 100.
14. Xu W, Yu L, Zhou W, Luo M. Resistin increases lipid accu-
mulation and CD36 expression in human macrophages. Bio-
chem Biophys Res Commun 2006; 351: 376.
15. Weikert C, Westphal S, Berger K, et al. Plasma resistin levels
and risk of myocardial infarction and ischemic stroke. J Clin
Endocrinol Metab 2008; 93: 2647.
16. Zhang MH, Na B, Schiller NB, Whooley MA. Association of
resistin with heart failure and mortality in patients with
stable coronary heart disease: data from the heart and soul
study. J Card Fail 2011; 17: 24.
17. Lee SH, Ha JW, Kim JS, et al. Plasma adiponectin and resis-
tin levels as predictors of mortality in patients with acute
myocardial infarction: data from infarction prognosis study
registry. Coron Artery Dis 2009; 20: 33.
360 © 2015 Steunstichting ESOT 29 (2016) 352–361
Resistin and outcomes Nagy et al.
18. Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M. Resistin, a
new adipokine, is related to inflammation and renal function
in kidney allograft recipients. Transplant Proc 2006; 38: 3434.
19. Molnar MZ, Czira ME, Rudas A, et al. Association of the
malnutrition-inflammation score with clinical outcomes in
kidney transplant recipients. Am J Kidney Dis 2011; 58: 101.
20. Molnar MZ, Tabak AG, Alam A, et al. Serum erythropoietin
level and mortality in kidney transplant recipients. Clin J
Am Soc Nephrol 2011; 6: 2879.
21. Kovesdy CP, Mucsi I, Czira ME, et al. Association of serum
phosphorus level with anemia in kidney transplant recipi-
ents. Transplantation 2011; 91: 875.
22. Molnar MZ, Czira ME, Rudas A, et al. Association between
the malnutrition-inflammation score and post-transplant
anaemia. Nephrol Dial Transplant 2011; 26: 2000.
23. Kovesdy CP, Czira ME, Rudas A, et al. Body mass index,
waist circumference and mortality in kidney transplant
recipients. Am J Transplant 2010; 10: 2644.
24. Kovesdy CP, Molnar MZ, Czira ME, et al. Associations
between serum leptin level and bone turnover in kidney
transplant recipients. Clin J Am Soc Nephrol 2010; 5: 2297.
25. Molnar MZ, Keszei A, Czira ME, et al. Evaluation of the
malnutrition-inflammation score in kidney transplant recip-
ients. Am J Kidney Dis 2010; 56: 102.
26. Jassal SV, Schaubel DE, Fenton SS. Baseline comorbidity in
kidney transplant recipients: a comparison of comorbidity
indices. Am J Kidney Dis 2005; 46: 136.
27. Levey AS, Stevens LA, Schmid CH, et al. A new equation to
estimate glomerular filtration rate. Ann Intern Med 2009;
150: 604.
28. Fine J, Gray R. A proportional hazards model for subdistri-
bution of a competing risk. J Am Stat Assoc 1999; 94: 496.
29. Malyszko J, Malyszko JS, Kozminski P, Pawlak K, Mysliwiec
M. Elevated resistin is related to inflammation and residual
renal function in haemodialysed patients. Nephrology 2007;
12: 246.
30. Axelsson J, Bergsten A, Qureshi AR, et al. Elevated resistin
levels in chronic kidney disease are associated with decreased
glomerular filtration rate and inflammation, but not with
insulin resistance. Kidney Int 2006; 69: 596.
31. Marouga A, Dalamaga M, Kastania AN, et al. Correlates of
serum resistin in elderly, non-diabetic patients with chronic
kidney disease. Clin Lab 2012; 59: 1121.
32. Fontana A, Spadaro S, Copetti M, et al. Association between
resistin levels and all-cause and cardiovascular mortality: a
new study and a systematic review and meta-analysis. PLoS
ONE 2015; 10: e0120419.
33. Lim S, Koo BK, Cho SW, et al. Association of adiponectin
and resistin with cardiovascular events in Korean patients
with type 2 diabetes: the Korean atherosclerosis study
(KAS): a 42-month prospective study. Atherosclerosis 2008;
196: 398.
34. Frankel DS, Vasan RS, D’Agostino RB Sr, et al. Resistin, adi-
ponectin, and risk of heart failure the Framingham offspring
study. J Am Coll Cardiol 2009; 53: 754.
35. Spoto B, Mattace-Raso F, Sijbrands E, et al. Resistin and all-
cause and cardiovascular mortality: effect modification by
adiponectin in end-stage kidney disease patients. Nephrol
Dial Transplant 2013; 28(Suppl 4): iv181.
36. Chung W, Jung ES, Shin D, et al. Low resistin level is associ-
ated with poor hospitalization-free survival in hemodialysis
patients. J Korean Med Sci 2012; 27: 377.
37. Chemaly ER, Hadri L, Zhang S, et al. Long-term in vivo
resistin overexpression induces myocardial dysfunction
and remodeling in rats. J Mol Cell Cardiol 2011; 51:
144.
38. Briffa JF, McAinch AJ, Poronnik P, Hryciw DH. Adipokines
as a link between obesity and chronic kidney disease. Am J
Physiol Renal Physiol 2013; 305: F1629.
39. Verma S, Li SH, Wang CH, et al. Resistin promotes
endothelial cell activation: further evidence of
adipokine-endothelial interaction. Circulation 2003; 108:
736.
40. Maggio AB, Wacker J, Montecucco F, et al. Serum resistin
and inflammatory and endothelial activation markers in
obese adolescents. J Pediatr 2012; 161: 1022.
41. Ichida Y, Hasegawa G, Fukui M, et al. Effect of atorvastatin
on in vitro expression of resistin in adipocytes and mono-
cytes/macrophages and effect of atorvastatin treatment on
serum resistin levels in patients with type 2 diabetes. Phar-
macology 2006; 76: 34.
42. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W,
Mantzoros CS. Short-term treatment with ezetimibe, sim-
vastatin or their combination does not alter circulating adi-
ponectin, resistin or leptin levels in healthy men. Clin
Endocrinol (Oxf) 2008; 68: 536.
43. Zhou YH, He XM, Yao Z. The effect of fluvastatin on serum
concentration of resistin in patients with chronic heart fail-
ure. Journal of Hainan Medical College 2009; 9: 039.
44. Holdaas H, Fellstrom B, Jardine AG, et al. Effect of fluvas-
tatin on cardiac outcomes in renal transplant recipients: a
multicentre, randomised, placebo-controlled trial. Lancet
2003; 361: 2024.
45. Falcao-Pires I, Castro-Chaves P, Miranda-Silva D, Lourenco
AP, Leite-Moreira AF. Physiological, pathological and
potential therapeutic roles of adipokines. Drug Discov Today
2012; 17: 880.
© 2015 Steunstichting ESOT 29 (2016) 352–361 361
Nagy et al. Resistin and outcomes
